Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25624
Title: Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
Austin Authors: Balasubramanian, Adithya ;Onggo, James;Gunjur, Ashray ;John, Thomas ;Parakh, Sagun 
Affiliation: School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Medical Oncology
Olivia Newton-John Cancer Research Institute
Department of Medical Oncology, Monash Health, Melbourne, Victoria, Australia
Department of Surgery, Eastern Health, Melbourne, Victoria, Australia
Issue Date: 2021
Date: 2020-11-12
Publication information: Clinical lung cancer 2021; 22(2): 74-82
Abstract: The role of immune checkpoint inhibitors (ICIs) administered concurrently with or after definitive chemoradiation (CRT) in stage III non-small-cell lung cancer (NSCLC) has been detailed in several studies. We performed a systematic review to determine pneumonitis rates using ICIs with CRT. MEDLINE and EMBASE databases were searched using keywords and MeSH terms. Studies using anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) therapy, either sequentially or concurrently with CRT, for patients with stage III NSCLC were included. A meta-analysis of pneumonitis rates was performed based on weighted pooled proportion, using random-effects models. Weighting was performed by the inverse variance or standard error of event rates. Comparative analysis between groups was performed. Odds ratios (OR) were used as the primary summary statistics. A total of 13 studies were identified (6 prospective clinical trials and 7 real-world reports). Rates of grade ≥ 3 pneumonitis were significantly higher in clinical trials using anti-PD-1 therapy compared with PD-L1 inhibitors (8.6%; 95% confidence interval [CI], 6.2%-11.9% vs. 4.4%; 95% CI, 3.0%-6.6%; OR, 2.0; P = .01). Clinical trials using concurrent ICI therapy with CRT had greater rates of grade 2 pneumonitis compared with sequential administration (23.0%; 95% CI, 15.8%-32.3% vs. 11.0%; 95% CI, 6.6%-17.8%; OR, 0.42; P = .02). Higher rates of grade ≥ 3 pneumonitis were observed in real-world studies compared with clinical trials involving sequential PD-L1 therapy (9.9%; 95% CI, 5.3%-17.9% vs. 4.4%; 95% CI, 2.9%-6.7%; OR, 0.43; P < .01). The suggestion of increased pneumonitis with a concurrent ICI strategy and using anti-PD-1 therapies warrants further consideration in future comparative studies.
URI: https://ahro.austin.org.au/austinjspui/handle/1/25624
DOI: 10.1016/j.cllc.2020.10.023
Journal: Clinical Lung Cancer
PubMed URL: 33414053
Type: Journal Article
Subjects: Durvalumab
Immunotherapy
NSCLC
PD-1 inhibitors
PD-L1 inhibitors
Appears in Collections:Journal articles

Show full item record

Page view(s)

64
checked on Jul 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.